Introduction
============

Polycystic ovary syndrome (PCOS), the most common endocrine disorder in women of reproductive age \[[@B1][@B2][@B3]\], is also the most common cause of anovulatory infertility \[[@B4]\]. As women with PCOS represent a group of high responders, multi-follicular growth is easily achieved through controlled ovarian stimulation (COS). However, the risk of ovarian hyperstimulation syndrome (OHSS) is markedly elevated in these patients \[[@B5]\].

The use of a gonadotropin-releasing hormone (GnRH) antagonist has advantages over GnRH agonist protocols in terms of a lower requirement for gonadotropins, reduced length of treatment, and reduced incidence of moderate-to-severe OHSS \[[@B6][@B7]\]. The GnRH antagonist is generally started either on a fixed schedule (i.e., day 6 of stimulation), or on a flexible schedule (i.e., appearance of a follicle greater than 14--15 mm in diameter). Both conventional methods start GnRH antagonists a few days after gonadotropin has been administered. In contrast, earlier initiation of the GnRH antagonist has been proposed to reduce exposure to luteinizing hormone (LH) and estradiol (E~2~) in the early follicular phase during COS, which negatively affects the probability of pregnancy \[[@B8]\]. Additionally, early administration of the GnRH antagonist may increase the oocyte yield by eliminating the asynchrony (size discrepancy) among growing follicles \[[@B9]\]. In two previous studies, the early antagonist protocol showed a similar number of oocytes retrieved, a similar pregnancy rate, and reduced OHSS rates compared to the long agonist protocol in PCOS patients \[[@B10],[@B11]\].

The purpose of this study was to investigate the efficacy and safety of administering a GnRH antagonist on the 1st day of COS compared to the conventional GnRH antagonist protocol and long agonist protocol through a randomized trial.

Methods
=======

1. Study design
---------------

This was a multi-center randomized parallel-group trial comparing three different protocols that incorporated different modes of GnRH analogue administration. The study complied with the Declaration of Helsinki and was approved by the Institutional Review Board of Seoul National University Hospital (IRB No. H-1012-114-345), and each participating hospital. This study has been registered at [ClinicalTrials.gov](http://www.ClinicalTrials.gov) (No. [NCT01402336](http://clinicaltrials.gov/ct2/show/NCT01402336)). Patients were enrolled from the following four university-based or university-affiliated hospitals, which submitted case report forms without rule violations: Seoul National University Hospital, CHA Gangnam Medical Center, CHA Bundang Medical Center, and Cheil General Hospital and Women\'s Healthcare Center.

Eligible participants had PCOS as defined by the Rotterdam criteria \[[@B12][@B13]\]. All women therefore had at least two of the three following characteristics: (1) oligo- or anovulation, (2) clinical and/or biochemical signs of hyperandrogenism, and (3) polycystic ovaries with the exclusion of other possible etiologies. Further inclusion criteria included: age 20--40 years; presence of both ovaries without ovarian tumors; a normal uterine cavity as assessed through an ultrasound scan, hysterosalpingograms, or hysteroscopy; normal renal, liver and hematological indices; normal thyroid function; and normal prolactin levels. The exclusion criteria were an extrauterine pregnancy or abortion in the past 3 months; abnormal gynecological bleeding of undetermined origin; a congenital uterine anomaly; congenital adrenal hyperplasia; androgen-secreting tumors; Cushing syndrome; any contraindication for recombinant follicle-stimulating hormone (rFSH), GnRH analogue, or human chorionic gonadotropin (hCG) administration; and severe male factor infertility. Eligible subjects were identified prospectively from women who planned to start an *in vitro* fertilization (IVF) or intracytoplasmic sperm injection (ICSI) treatment cycle. Written informed consent was obtained from each woman who wished to participate. After confirming patient eligibility, a blood test was performed to obtain the baseline female reproductive hormone profile, and height and weight were measured. Patients were randomized 1:1:1 to the following three groups using a web-based system: the day 1 antagonist group, the day 6 antagonist group, or the long agonist group. The web-based system was provided by the Medical Research Collaborating Center of Seoul National University Hospital (SNUH; <https://mrcc.snuh.org>). Stratified randomization was used (stratification according to the institution, block randomization with a randomly selected block size). The investigator was blind to the randomization process, including the size of each block. Neither patients nor doctors were blinded to the treatment assigned. Any patients who withdrew their consent continued with their routine IVF treatment and were excluded from the analysis. All serious adverse events were submitted to the Clinical Trials Unit, Seoul National University Hospital, and the trial was evaluated periodically by an independent data and safety monitoring board.

2. Controlled ovarian stimulation
---------------------------------

The schematic representation of each protocol is shown in [Figure 1](#F1){ref-type="fig"}. All subjects received oral contraceptive pills (OCPs) for 21 days starting on menstrual day 5 in the cycle prior to the treatment cycle. An OCP containing ethinyl E~2~ (0.03 mg) and cyproterone acetate (2 mg) (Diane-35; Bayer AG, Leverkusen, Germany) was recommended, but other OCPs were permitted. A starting dose of 150 IU of rFSH (300 IU, 450 IU, 900 IU; Gonal-F, Merck Serono, London, UK) was recommended, but alterations were allowed if necessary ([Table 1](#T1){ref-type="table"}). GnRH analogues were administered as described below.

### 1) The early antagonist group

Patients in this group started daily rFSH treatment on the 3rd day of withdrawal bleeding following OCP administration. A subcutaneous dose of 0.25 mg of cetrorelix (0.25 mg; Cetrotide, Merck Serono) was also started on the same day and continued daily through the day of hCG administration, inclusively.

### 2) The conventional antagonist group

FSH treatment was initiated on the 3rd day of withdrawal bleeding and was continued as in the early antagonist group. A daily concomitant subcutaneous dose of 0.25 mg of cetrorelix (0.25 mg; Cetrotide, Merck Serono) was started on the 6th day of stimulation. Treatment with this GnRH antagonist continued daily through the day of hCG administration, inclusively.

### 3) The long agonist group

Patients received a subcutaneous dose of 0.1 mg of triptorelin (0.1 mg; Decapeptyl, Ferring, Kiel, Germany) daily, starting on the 18th day of OCP administration (i.e., with 4 days of overlap). FSH treatment was initiated on the 3rd day of withdrawal bleeding and continued as in the early antagonist group and the conventional antagonist group. Starting from the 1st day of rFSH treatment, the dose of triptorelin was reduced to 0.05 mg daily and was continued through the day of hCG administration, inclusively.

3. Oocyte retrieval, fertilization, and transfer
------------------------------------------------

Recombinant hCG (250 µg; Ovidrel, Merck Serono) or urinary hCG (10,000 IU; IVF-C, LG Life Sciences, Iksan, Korea) was administered when at least two follicles reached 17 mm in diameter. Oocyte retrieval was performed 36--38 hours following hCG administration, and fertilization was carried out using IVF, ICSI or half ICSI following the investigator\'s decision. For luteal support, daily vaginal progesterone (Crinone, Merck Serono) was started on the day of oocyte retrieval and was continued up to 8 weeks. When severe OHSS was anticipated, embryo transfer was waived, and all embryos were cryopreserved. Since many different criteria exist for performing cryopreservation of all embryos for OHSS prevention, and the purpose of this study was not to evaluate the OHSS prevention strategy, the decision was left to the clinicians. Embryo transfer was performed 2--5 days after oocyte retrieval, and a serum hCG test was performed 2 weeks after fertilization to confirm pregnancy. The gestational sac and fetal heartbeat were identified using transvaginal ultrasound in patients weekly thereafter.

4. Assessment of embryo quality
-------------------------------

The morphological assessment of day 3 embryos was performed according to the following criteria: grade 1, blastomeres of equal size, no cytoplasmic fragments; grade 2, blastomeres of equal size, minor cytoplasmic fragments or blebs; grade 3, blastomeres of distinctly unequal size, few or no cytoplasmic fragments; grade 4, blastomeres of equal or unequal size, significant cytoplasmic fragmentation; grade 5, few blastomeres of any size, severe or complete fragmentation. Good-quality embryos were defined as grade 1 or grade 2 embryos. Blastocysts were evaluated on day 5 using a scoring system based on the expansion state of the blastocyst and the consistency of the inner cell mass and trophectoderm cells. Good-quality embryos were defined as those with a score of 3BB or higher.

5. Study endpoints
------------------

The primary endpoint of this study was the number of oocytes retrieved. The secondary endpoints were the clinical pregnancy rate and the occurrence of moderate-to-severe OHSS. The classification by Golan and Weissman \[[@B14]\] was used to assess the severity of OHSS.

6. Power analysis
-----------------

We set the baseline number of oocytes retrieved in the GnRH agonist long protocol for PCOS patients to be 13.2±5.8 based on the study by Bahceci et al. \[[@B15]\] and the SNUH data (unpublished), and the detectable difference between groups at 4.9, assuming an α level of 0.025. The α level was halved since we compared the early antagonist group with two other groups. It was calculated that a sample size of 80 patients was required in each group to achieve a 0.80 power. Such a sample size (80 patients per group) is not easily achieved even in a multicenter study, when studying a small proportion of the population, such as PCOS patients who undergo IVF. The previous two studies on this topic reported 49 patients \[[@B10]\] and 78 patients \[[@B11]\] and we initiated this study because we thought we could provide useful clinical information, even with small number of subjects.

7. Statistical analysis
-----------------------

The results of this preliminary report are presented as median (range), and nonparametric tests were used for statistical analysis. Continuous variables, including the primary endpoint (number of oocytes retrieved) were compared using the Kruskal-Wallis test. The comparison of the frequency of features, including the secondary endpoints (the clinical pregnancy rate and the occurrence of moderate-to-severe OHSS) were performed using the chi-square test. All statistical analyses were performed using IBM SPSS ver. 22.0 (IBM Corp., Armonk, NY, USA). The α level of significance was set at 0.05.

Results
=======

1. Patient enrollment and baseline characteristics
--------------------------------------------------

Between February 2011 and December 2016, a total of 36 infertile women with PCOS were enrolled in this study, after the exclusion of seven women who discontinued participation after the initial agreement ([Figure 2](#F2){ref-type="fig"}). One cycle in the early antagonist group was cancelled due to poor ovarian response, leaving a total of 35 cycles eligible for OHSS surveillance. No oocyte was retrieved in one patient in the conventional antagonist group. The cryopreservation of all embryos without embryo transfer was performed in a total of eight patients; seven of these procedures were performed to prevent OHSS, and one was due to hemoperitoneum. Embryo transfer was performed in the remaining 26 cycles. Age, body mass index, and base-line hormone levels were comparable in all three groups ([Table 1](#T1){ref-type="table"}). The characteristics of the cycles are shown in [Table 2](#T2){ref-type="table"}, and the IVF outcomes are shown in [Table 3](#T3){ref-type="table"}.

2. Primary outcome
------------------

The number of oocytes retrieved was greatest in the long agonist group (n=19), followed by the early antagonist group (n=16) and the conventional antagonist group (n=12). However, the difference was not statistically significant (*p*=0.111). The number of mature oocytes retrieved also followed a similar order, and likewise no statistically significant difference was observed among the early antagonist (n=10.5), conventional antagonist (n=8), and long agonist (n=13) groups (*p*=0.112).

3. Secondary outcome
--------------------

The clinical pregnancy rate was greatest in the early antagonist group (50.0%), followed by the long agonist group (22.2%) and the conventional antagonist group (11.1%), although this difference was not statistically significant (*p*=0.180).

The incidence of moderate-to-severe OHSS was lowest in the early antagonist group (7.7%), followed by the conventional antagonist group (18.2%) and the long agonist group (27.3%). However, this trend was not statistically significant (*p*=0.463). The incidence of moderate-to-severe OHSS among patients at high risk for OHSS (E~2~ concentration on hCG day \>2,000 pg/mL) was lowest in the early antagonist group (12.5%), in contrast to the conventional antagonist group (40%) and the long agonist group (50.0%), but this difference was also not statistically significant (*p*=0.324).

4. Others
---------

The duration of stimulation was similar among the three groups. A higher starting dose of FSH seemed to be preferred in the long agonist group, but there was no statistically significant difference among the three groups. The total dose of gonadotropin was greatest in the early antagonist group (median, 1,931 IU), followed by the long agonist group (median, 1,800 IU) and conventional antagonist group (median, 1,350 IU), but the difference was not statistically significant. Although the E~2~ concentration on day 6 seemed to be much higher in the early antagonist group than in the conventional antagonist group, the difference was not statistically significant. The E~2~ concentration on the day of hCG administration was highest in the early antagonist group (median, 3,795 pg/mL), and was lowest in the conventional antagonist group (median, 969 pg/mL), but the difference was not statistically significant. The number of large follicles on the hCG day was slightly higher in the early antagonist group than in the conventional antagonist group, but this difference did not reach statistical significance. There was no difference in oocyte maturity among the three groups (*p*=0.800). The number of cycles that underwent embryo cryopreservation for OHSS prevention was greatest in the early antagonist group (n=4). The reason for this may have been the high E~2~ concentration on the day of hCG although the difference from other groups was not statistically significant. However, COS was not more intense in the patients with OHSS in the early antagonist group since the median total dose of gonadotropin was not significantly different between patients with OHSS (2,006.25 IU) and patients without OHSS (1,650 IU, *p*=0.708).

Discussion
==========

To our knowledge, this is the first randomized clinical trial to compare these three different protocols---namely, the early antagonist protocol, the conventional antagonist protocol, and the long agonist protocol---in PCOS patients. This prospective randomized study sought to determine whether there were differences in the number of oocytes retrieved, pregnancy outcomes, and the incidence of moderate-to-severe OHSS among three different COS protocols. We found no difference in the number of total oocytes and mature oocytes retrieved, the clinical pregnancy rate, or the incidence of moderate-to-severe OHSS among the three different protocols.

To prevent a premature LH surge during COS, GnRH analogues are used to achieve pituitary suppression. GnRH agonists were the first to appear in clinical practice, and were commonly administered at the midluteal phase of the preceding menstrual period to avoid the initial flare effect (the GnRH agonist long protocol). The major disadvantages of the GnRH agonist long protocol are the long duration of administration, vasomotor symptoms associated with estrogen deprivation, the induction of unwanted ovarian cysts, and a high incidence of OHSS \[[@B16],[@B17]\].

GnRH antagonists, introduced in the 2000s, could be administered during COS. GnRH antagonists suppress the pituitary immediately by competing directly with endogenous GnRH. Compared to the GnRH agonist long protocol, the GnRH antagonist protocol has the advantages of a shorter duration of stimulation, reduced gonadotropin dose requirements, a lower cycle cancellation rate, lower peak E~2~ levels, and a lower incidence of OHSS. The ongoing pregnancy rate and live birth rate have been found to be comparable to those obtained using long GnRH agonist protocols \[[@B7][@B18][@B19][@B20]\]. While administering a GnRH antagonist in the midfollicular phase has the above advantages, it was found that follicular development showed poor synchronization (i.e., greater size heterogeneity among growing follicles during COS) compared to the GnRH agonist long protocol, resulting in fewer follicles being visible on the day of hCG administration and fewer oocytes being retrieved. The absence of pituitary suppression during the first few days of COS may have caused the follicular asynchrony, and starting the GnRH antagonist earlier during COS may theoretically improve asynchrony among follicles, thereby increasing the oocyte yield and eliminating the potential detrimental effects of early follicular exposure to LH and E~2~ \[[@B8]\]. However, controversy emerged regarding whether earlier GnRH antagonist administration would increase the gonadotropin dose requirement, increase E~2~ levels on the day of hCG, or have any effects on pregnancy outcomes and the incidence of OHSS \[[@B8][@B9][@B11][@B21]\].

Several attempts have been made to introduce the early administration of GnRH antagonists during COS in women with PCOS. Hwang et al. \[[@B10]\] started a GnRH antagonist on the 3rd day following withdrawal bleeding after three cycles of OCP pretreatment. Gonadotropins were administered on the 4th day following withdrawal bleeding. Compared to the long agonist protocol, they found similar pregnancy rates (40% vs. 41.7%, not significant) and similar OHSS rates (8.0% vs. 8.3%, not significant), but the early antagonist protocol required less gonadotropin (21.6±6.3 vs. 25.9±7.2 ampules of human menopausal gonadotropin, *p*\<0.05) and the peak E~2~ level was lower on the day of hCG administration (2,159±690 pg/mL vs. 2,633±775 pg/mL, *p*\<0.05). Lainas et al. \[[@B11]\] also compared the early antagonist protocol with the long agonist protocol in PCOS patients and observed no difference in the number of oocytes retrieved (26.0 vs. 29.0, *p*=0.166), E~2~ levels on the day of hCG administration (2,333 pg/mL vs. 2,858 pg/mL, *p*=0.153), or clinical (57.7% vs. 61.5%, *p*=0.808) and ongoing pregnancy rates (46.2% vs. 48.1%, *p*=0.999). However, the incidence of OHSS was significantly lower in the early antagonist group (11.54%) than in the long agonist group (38.46%, *p*=0.02).

Whether the early administration of GnRH antagonists improves follicular asynchrony has been an area of debate. Kolibianakis et al. \[[@B21]\] reported no difference in the size distribution of follicles on the day of hCG administration between early and conventional antagonist groups in non-PCOS patients. Lainas et al. \[[@B11]\] reported that a similar number of oocytes was retrieved in the early antagonist protocol and in the long agonist protocol in PCOS patients. In contrast, a higher number of mature oocytes was retrieved in the early antagonist protocol than in the conventional antagonist protocol in non-PCOS patients \[[@B9]\]. Our results are similar to those of a study by Lainas et al. \[[@B11]\] and Kolibianakis et al. \[[@B21]\], and there was no difference in follicle size distribution or the number of total/mature oocytes retrieved.

The main strength of our study is that we compared the early antagonist protocol with two widely used protocols. The long agonist protocol mainly served as a control for the number of oocytes retrieved when there was excellent follicle synchronization. There was no difference in the follicle size distribution on the day of hCG administration or in the number of oocytes retrieved. In contrast, the conventional antagonist group served as controls to assess the effect of the additional 5 days of GnRH antagonist administration in terms of a possible increase in gonadotropin dose requirements as well as the primary and secondary outcomes. The total gonadotropin dose in the early antagonist group was higher than in the conventional antagonist group, but the difference was not statistically significant. Both the total number of oocytes and the number of mature oocytes were higher in the early antagonist group than in the conventional antagonist group, but these differences were likewise not statistically significant.

A major limitation of this study was the long recruitment phase. A possible explanation for this is that the candidates preferred a dedicated treatment plan and were reluctant to participate in a randomized trial during their fertility treatment. The small sample size was another limitation. There were differences in the number of oocytes retrieved, clinical pregnancy rates, and the incidence of moderate-tosevere OHSS, but statistical significance was not reached. Differences in those primary- and secondary outcome measures were not detected in our study with the possibility of type II error.

In conclusion, we compared three different ovarian stimulation protocols in PCOS patients. Early administration of a GnRH antagonist may possibly yield benefits due to a reduction in the incidence of moderate-to-severe OHSS in high-risk subjects with a similar number of oocytes retrieved, as well as a better clinical pregnancy rate per embryo transfer. To clarify these issues, further studies with more subjects are required.
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![Schematic representation of each *in vitro* fertilization protocol. GnRH, gonadotropin-releasing hormone; rFSH, recombinant folliclestimulating hormone; hCG, human chorionic gonadotropin; MCD, menstrual cycle day.](cerm-45-135-g001){#F1}

![Flow diagram of the steps of the randomized trial. OCs, oral contraceptives; OHSS, ovarian hyperstimulation syndrome; hCG, human chorionic gonadotropin.](cerm-45-135-g002){#F2}

###### Baseline characteristics and hormonal profile of the study groups

![](cerm-45-135-i001)

Values are presented as median (range) or number (%).

BMI, body mass index; AFC, antral follicle count; AMH, anti-Müllerian hormone; LH, luteinizing hormone; FSH, follicle-stimulating hormone; E~2~, estradiol.

###### Cycle characteristics in the study groups
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Values are presented as median (range).

NA, not applicable; E~2~, estradiol; hCG, human chorionic gonadotropin.

###### IVF outcomes of the study groups
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Values are presented as number (%) or median (range).

IVF, *in vitro* fertilization; ICSI, intracytoplasmic sperm injection; NA, not applicable; OHSS, ovarian hyperstimulation syndrome; E~2~, estradiol; hCG, human chorionic gonadotropin.
